diabetes

For decades, the fight against obesity and type 2 diabetes has been marred by limited tools and frustrating plateaus. Patients and clinicians alike have navigated a landscape of diets with high relapse rates, medications with modest efficacy and significant side effects. However, a seismic shift is underway, centered on a humble gut hormone: Glucagon-Like Peptide-1 (GLP-1). Once an obscure biological pathway studied by endocrinologists, GLP-1 has given rise to a new class of pharmaceuticals that not only manage symptoms, but also fundamentally reshape metabolic health. The benefits of GLP-1 extend far beyond blood sugar control.